ERBB2 and obstructive sleep apnea syndrome: A previous study of monoclonal antibody Trastuzumab as an adjuvant therapy showed no clinical benefit in HER2-overexpressed OSA patients; the overall survival rate for 30 months is 59% in HER2-overexpressed patients and 50% in a patient group with overexpression [56].